When was Concarlo founded?

Concarlo was founded in 2015 and raised its 1st funding round 2 years after it was founded.

Where is Concarlo located?

Concarlo is headquartered in Brooklyn, United States.

How many employees does Concarlo have?

As of Aug 31, 2026, the latest employee count at Concarlo is 12.

Is Concarlo a funded company?

Concarlo is a funded company, having raised a total of $1.45M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 23, 2017.

When was the latest funding round of Concarlo?

Concarlo's latest funding was a $***** Grant (prize money) round on Jul 10, 2020, with participation from 1 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $4.45B in funding in 2026 to date.

Where does Concarlo rank among its competitors?

Concarlo ranks 101st amongst 256 active competitors, of which 94 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was ScreenPoint, which secured $14M in Apr, 2026.

Who are the top competitors of Concarlo?

Concarlo's top competitors include Xilio Therapeutics, Harbour BioMed and ScreenPoint. Among them, ScreenPoint secured the most recent funding round in April, 2026.

Concarlo - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapies for treating breast cancer. The company's patented technology specifically addresses drug resistance breast cancers. They are developing polyclonal antibodies which inhibit cyclin-dependent kinases (cdk4) and reduces the chance of resistance.

Website: concarlo.com
Email ID: *****@concarlo.com
Phone Number: +1 **********

Key Metrics

Founded Year

2015

Location

Brooklyn, United States

Stage

Seed

Total Funding

$1.45M in 3 rounds

Latest Funding Round

Grant (prize money), Jul 10, 2020, $*****

Investors

BioAdvance & 6 more

Ranked

101^st among 256 active competitors

Employee Count

12 as on Aug 31, 2026

Similar Companies

Xilio Therapeutics & 338 more

View Concarlo's full profile

Concarlo has raised a total funding of $1.45M over 3 rounds. Its first funding round was on Mar 23, 2017. Its latest funding round was a Grant (prize money) round on Jul 10, 2020 for $*****. 1 investor participated in its latest round. Concarlo has 7 institutional investors.

Here is the list of recent funding rounds of Concarlo:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 10, 2020	9802816	Grant (prize money)	5365132	6062932	6351006	7404044
Mar 21, 2018	1457120	Seed	6396627	8369562	8407380	Accelerate NY Seed Fund
Mar 23, 2017	3486354	Seed	8956064	1236418	9106229	9549387

Access funding benchmarks and valuations. Sign up today!

View details of Concarlo's funding rounds and investors

The founders of Concarlo are LisaMarie Casey and Stacy Blain. Arikha Moses is the CEO of Concarlo.

Here are the details of Concarlo's key team members:

LisaMarie Casey: Co-Founder of Concarlo.
Contact Info: 1 email address
Stacy Blain: Former Co-Founder of Concarlo.
Arikha Moses: CEO of Concarlo.

View details of Concarlo's Founder profiles and Board Members

Concarlo's employee count trend

Concarlo has 12 employees as of Aug 26. Here is Concarlo's employee count trend over the years:

Uncover Concarlo's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Concarlo include Xilio Therapeutics, Harbour BioMed and ScreenPoint. Here is the list of Top 10 competitors of Concarlo, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Xilio Therapeutics 2016, Waltham (United States), Public	Developer of immunotherapies for the treatment of cancer	$233M	F-Prime Capital, Atlas Venture & 16 others	67/100
2nd	Harbour BioMed 2016, Shanghai (China), Public	Developer of antibody therapeutics in immunology and oncology disease	$313M	GIC, Hudson Bay Capital & 19 others	66/100
3rd	ScreenPoint 2014, Nijmegen (Netherlands), Series C	Developer of artificial intelligence software for analyzing breast imaging mammograms	$47M	Siemens, Insight Partners & 3 others	64/100
4th	AVEO Pharmaceuticals 2001, Cambridge (United States), Acquired	Developer of small molecules of drugs for the treatment of cancer	$146M	Hercules Capital, Biogen & 14 others	61/100
5th	Orum Therapeutics 2016, Daejeon (South Korea), Public	Developer of cell-penetrating antibodies as oncology therapeutics	$92M	IMM Investment, KTB Network & 19 others	60/100
6th	Immunome 2008, Philadelphia (United States), Public	Developer of antibody-based therapeutics for treating cancer	$54.2M	BioAdvance, Evolution VC Partners & 4 others	60/100
7th	BioAtla 2007, San Diego (United States), Public	Developer of immunotherapies for cancer using active biologics platform	$162M	HBM Healthcare Investments, Soleus Capital ... & 15 others	60/100
8th	Genenta Science 2014, Milan (Italy), Public	Developer of lentivirus-based gene and cell therapies for cancer	$33.6M	Mediobanca, Qianzhan & 4 others	59/100
9th	Oncoinvent 2010, Oslo (Norway), Public	Developer of radioisotope-based anti-cancer therapeutics	$30.7M	Hadean Ventures, Canica & 8 others	58/100
10th	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	CTI Life Sciences Fund, Advanced Biotechnologies Venture Fund ... & 17 others	57/100
101st	Concarlo 2015, Brooklyn (United States), Seed	Developer of therapies for treating breast cancer	$1.45M	BioAdvance, Springboard Enterprises & 5 others	35/100